AUTHOR=Chen Zhang-Ren , Zhou Ying , Liu Jin , Peng Hong-Wei , Zhou Jian , Zhong Hai-Li , Liu Li-Li , Lai Ming-Fang , Wei Xiao-Hua , Wen Jin-Hua 

TITLE=Pharmacotherapics Advice in Guidelines for COVID-19

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 11 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00950

DOI=10.3389/fphar.2020.00950

ISSN=1663-9812

ABSTRACT=Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to the sudden and rapid outbreak, the effective treatment of COVID-19 is scarce. Based on the national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine,  and tocilizumab. In this paper, we summarized the pharmacotherapy of those guidelines for COVID-19, highlighted the updates of the pharmacotherapy of those guidelines, and reviewed the efficacy and safety of those anti-COVID-19 drugs.